Autolus Therapeutics plc (AUTL) Free cash flow
- Free cash flow · 12 months (USD): Value $-232.73M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -198.26%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-232.73M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-225.61M − $7.12M ≈ $-232.73M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -198.26% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-232.73M ÷ $117.39M × 100 ≈ -198.26% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-225.61M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.81× | Operating cash flow / net income. Period ending 2026-06-30. $-225.61M ÷ $-280.16M ≈ 0.81× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -225.61M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 7.12M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -232.73M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 117.39M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | |
| Net income | -280.16M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-232.73M | (m) | $-225.61M | $7.12M | (m) | $117.39M | (m) | $-280.16M | (m) | (m) | -198.26% | 0.81× |
| 2026-03-31 | $-286.81M | (m) | $-273.32M | $13.49M | (m) | $92.62M | (m) | $-288.96M | (m) | (m) | -309.65% | 0.95× |
| 2025-12-31 | $-302.61M | (m) | $-283.57M | $19.04M | (m) | $75.39M | (m) | $-287.53M | (m) | (m) | -401.40% | 0.99× |
| 2025-09-30 | $-285.22M | (m) | $-254.18M | $31.04M | (m) | $51.13M | (m) | $-224.80M | (m) | (m) | -557.85% | 1.13× |
| 2025-06-30 | $-299.24M | (m) | $-263.02M | $36.22M | (m) | $29.93M | (m) | $-227.78M | (m) | (m) | -999.67% | 1.15× |
| 2025-03-31 | $-271.11M | (m) | $-241.32M | $29.79M | (m) | $9.01M | (m) | $-238.13M | (m) | (m) | -3008.62% | 1.01× |
| 2024-12-31 | $-228.35M | (m) | $-206.27M | $22.07M | (m) | $10.12M | (m) | $-220.66M | (m) | (m) | -2256.38% | 0.93× |
| 2024-09-30 | $-205.61M | (m) | $-193.17M | $12.44M | (m) | (m) | (m) | $-270.23M | (m) | (m) | (m) | 0.71× |
| 2024-06-30 | $-160.97M | (m) | $-156.62M | $4.35M | (m) | (m) | (m) | $-233.98M | (m) | (m) | (m) | 0.67× |
| 2024-03-31 | $-151.58M | (m) | $-143.68M | $7.90M | (m) | (m) | (m) | $-221.26M | (m) | (m) | (m) | 0.65× |
| 2023-12-31 | $-156.57M | (m) | $-145.59M | $10.99M | (m) | (m) | (m) | $-208.38M | (m) | (m) | (m) | 0.70× |
| 2023-09-30 | $-145.46M | (m) | $-135.32M | $10.14M | (m) | (m) | (m) | $-158.16M | (m) | (m) | (m) | 0.86× |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-151.59M | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-123.15M | (m) | $-112.31M | $10.84M | (m) | (m) | (m) | $-148.84M | (m) | (m) | (m) | 0.75× |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-126.72M | (m) | $-117.86M | $8.86M | (m) | (m) | (m) | $-142.10M | (m) | (m) | (m) | 0.83× |
| 2021-03-31 | $-145.01M | (m) | $-131.07M | $13.94M | (m) | (m) | (m) | $-145.49M | (m) | (m) | (m) | 0.90× |
| 2020-12-31 | $-132.44M | (m) | $-117.76M | $14.68M | (m) | (m) | (m) | $-142.09M | (m) | (m) | (m) | 0.83× |
| 2020-09-30 | $-134.09M | (m) | $-123.30M | $10.80M | (m) | (m) | (m) | $-140.18M | (m) | (m) | (m) | 0.88× |
| 2020-06-30 | $-119.25M | (m) | $-108.72M | $10.53M | (m) | $1.24M | (m) | $-130.11M | (m) | (m) | -9640.10% | 0.84× |
| 2020-03-31 | $-112.65M | (m) | $-99.00M | $13.65M | (m) | $1.28M | (m) | $-126.54M | (m) | (m) | -8786.90% | 0.78× |
| 2019-12-31 | $-119.83M | (m) | $-101.48M | $18.34M | (m) | $2.91M | (m) | $-123.85M | (m) | (m) | -4120.53% | 0.82× |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-103.55M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | $3.01M | (m) | $-68.34M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | $-42.52M | (m) | (m) | $1.47M | (m) | $-57.88M | (m) | (m) | (m) | 0.73× |
| 2018-09-30 | $-40.66M | (m) | $-31.54M | $9.12M | (m) | $1.41M | (m) | $-44.75M | (m) | (m) | -2889.55% | 0.70× |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $-19.24M | (m) | $-16.36M | $2.88M | (m) | $1.69M | (m) | $-19.73M | (m) | (m) | -1136.21% | 0.83× |
| 2016-09-30 | $-11.70M | (m) | $-9.85M | $1.85M | (m) | $1.21M | (m) | $-12.55M | (m) | (m) | -965.68% | 0.78× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |